Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
H. Lundbeck A/S (Lundbeck) expands its pipeline of pharmaceuticals inclinical development by initiating phase II trials with the compoundLu AE58054. The compound is a new pharmaceutical candidate inLundbeck's portfolio and represents a novel approach to the treatmentof schizophrenia. Lu AE58054 has shown positive results in a number of preclinicaltrials, which documented the compound's ability to improve cognition.Affecting other areas of the brain than traditional anti-psychotics,the compound has an effect that breaks with tradition. In this way,Lu AE58054 complements the existing